Item 5. Other Information
Item 5. Other Information
During the three months ended
June 30, 2026, no director or officer of the Company adopted or terminated any contract, instruction or written plan for the purchase
or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or any “non-Rule 10b5-1
trading arrangement” as defined in Item 408(c) of Regulation S-K.
| June 30, 2026, Form 10-Q
33
Table of Contents
Item 6. Exhibits
Exhibit
Number
Exhibit
Description
3.1
Amended and
Restated Articles of Incorporation of the Registrant, as amended on August 1, 2012 (incorporated by reference to Exhibit 3.1 to the
Company’s Current Report on Form 8-K filed on August 6, 2012).
3.2
Articles of
Amendment to the Company’s Amended and Restated Articles of Incorporation filed with the State Department of Assessments and
Taxation of Maryland on March 7, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K
filed on March 21, 2023).
3.3
By-laws of
the Registrant (incorporated by reference to Exhibit 3.2 to the Company’s Post-Effective Amendment No.1 to Form S-3 filed on
January 22, 2021).
3.4
Amendment to
the Amended and Restated Articles of Incorporation of the Registrant as amended on August 2, 2014 (incorporated by reference to Exhibit
3.3 to the Company’s Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021).
3.5
Amendment to
the Bylaws of the Company dated March 2, 2023 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on
Form 8-K filed on March 21, 2023).
10.1
Subscription
Agreement, among the Company and the Investors (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on
Form 8-K filed on January 5, 2026).
10.2
Securities
Purchase Agreement, dated March 5, 2026, by and between IGC Pharma, Inc. and Vanquish Funding Group Inc. (incorporated by reference
to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 12, 2026).
10.3
Promissory
Note, dated March 5, 2026, issued by IGC Pharma, Inc. to Vanquish Funding Group Inc. in the aggregate principal amount of $353,050
(incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on March 12, 2026).
10.4
Loan
Agreement, dated February 9, 2026, by and between HH Processors, LLC and ODK Capital LLC (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on March
12, 2026).
10.5
Securities Purchase Agreement, by and between IGC Pharma, Inc. and FirstFire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 20, 2026).
10.6
Promissory Note issued by IGC Pharma, Inc. to FirstFire Global Opportunities Fund, LLC in the aggregate principal amount of $346,910 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on April 20, 2026).
10.7*
Amendment #1, dated June 18, 2026, to the Securities Purchase Agreement and Promissory Note, by and between IGC Pharma, Inc. and FirstFire Global Opportunities Fund, LLC.
10.8
Securities Purchase Agreement, by and between IGC Pharma, Inc. and Vanquish Funding Group Inc. (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on April 20, 2026).
10.9
Promissory Note issued by IGC Pharma, Inc. to Vanquish Funding Group Inc. in the aggregate principal amount of $238,050 (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on April 20, 2026).
10.10
Stock Purchase Agreement, dated June 30, 2026, by and between IGC Pharma, Inc. and each of Mr. Ram Mukunda and Ms. Claudia Grimaldi (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 6, 2026).
10.11
2026 O-Bank General Banking Facility Letter (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 8, 2026).
31.1*
Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.
31.2*
Rule 13a-14(a) / 15d-14(a) Certification of Principal Financial Officer.
32.1**
Certifications pursuant to 18 U.S.C. §1350.
101.INS*
Inline
XBRL Instance Document.
101.SCH*
Inline
XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline
XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB*
Inline
XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
Inline
XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF*
Inline
XBRL Taxonomy Extension Definition Linkbase Document.
104*
Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
*
Filed herewith.
**
Furnished herewith.
| June 30, 2026, Form 10-Q
34
Table of Contents
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
IGC PHARMA, INC.
Date: August 14, 2026
By:
/s/ Ram Mukunda
Ram Mukunda
President and Chief Executive Officer
(Principal Executive Officer)
Date: August 14, 2026
By:
/s/ Claudia Grimaldi
Claudia Grimaldi
Vice-President & Chief Compliance Officer
(Principal Financial Officer)
| June 30, 2026, Form 10-Q
35
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.